Saturday 17 October 2026
Export CGTX’s income statement to Excel — free account
Cognition Therapeutics, Inc.
CGTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.6% and free cash flow grew 45.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.73
0.00
0.00%
Follow CGTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
7.03 | 5.92 | 3.45 | 6.44 |
+8 more quarters Free account |
Net Debt/EBITDA |
4.52 | 3.57 | 2.72 | 6.31 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 1.21 | 1.03 | 1.15 | |
Capex/Depreciation |
(0.36) | 0.00 | 0.15 | 0.00 | |
Interest Coverage |
(2,579.33) | (1,763.40) | (2,734.20) | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.03) | (0.06) | (0.05) | (0.07) | |
Cash per Share |
0.38 | 0.35 | 0.51 | 0.51 | |
Shareholders Equity per Share |
0.36 | 0.34 | 0.47 | 0.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.36 | 0.34 | 0.47 | 0.47 | |
Free Cash Flow |
(3.07) | (5.54) | (3.43) | (5.65) | |
Working Capital |
32.85 | 29.76 | 34.07 | 36.23 | |
Capital Expenditures |
(0.02) | — | 0.01 | — | |
Net Current Asset Value |
32.43 | 29.59 | 33.87 | 36.02 | |
| Other line items | |||||
Quick Ratio |
6.92 | 5.76 | 3.37 | 6.27 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.03) | (0.06) | (0.05) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
4.62 | 4.22 | 6.30 | 2.63 | |
Average Payables |
0.72 | 2.84 | 1.55 | 1.36 | |
Average Assets |
29.26 | 29.82 | 39.31 | 35.49 | |
Average Common Equity |
20.03 | 21.09 | 26.51 | 25.51 | |
Capex to Sales |
0.00 | — | 0.00 | — |
Columns are period end dates